Institution Directory

Clinical trials at NYU Langone Health

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 7:55 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1143

Shown on this page

Current sort

Live official records

Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: Neladalkib (NVL-655), Midazolam, Repaglinide, Itraconazole; Drug
Lead sponsor: Nuvalent Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 21
States / cities: Orange, California • Sacramento, California • Stanford, California + 16 more

Conditions: Percutaneous Coronary Intervention, Valve Repair/Replacement, Coronary Artery Bypass Grafting
Interventions: EHR Nudges; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Non Small Cell Lung Cancer
Interventions: DRP-104; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: New York, New York

Conditions: Muscle Tension Dysphonia
Interventions: Standard of care voice therapy with novice clinician RTSS-Voice documentation, Standard of care voice therapy with expert clinician RTSS-Voice documentation; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more

Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Interventions: LY4101174; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Orlando, Florida • Atlanta, Georgia • Boston, Massachusetts + 5 more

Conditions: Spondyloarthritis, Inflammatory Bowel Diseases
Interventions: Guselkumab; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan; Drug
Lead sponsor: OncoC4, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 23
States / cities: Sacramento, California • Aurora, Colorado • Tampa, Florida + 19 more

Conditions: Hypertension, Pregnancy Induced
Interventions: High-touch blood pressure management, Low-touch blood pressure management; Other
Lead sponsor: Jennifer Lewey, MD, MPH; Other
Eligibility: 18 Years and older · Female only
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: New York, New York • Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Non Small Cell Lung Cancer
Interventions: Nivolumab, Ramucirumab; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Pancreatic Surgery
Interventions: The Fresenius Kabi C.A.T.S®plus Continuous AutoTransfusion System; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes
Interventions: CHW-led T2D Intervention; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: B-cell Non-Hodgkins Lymphoma (B-NHL)
Interventions: Odronextamab, REGN5837; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 9
States / cities: Duarte, California • Santa Monica, California • Louisville, Kentucky + 4 more

About this NYU Langone Health institution page

What this page lists: ClinicalTrials.gov records that list NYU Langone Health in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at NYU Langone Health

Filter and sort this campus

Live official records

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Cardiac Rehab Referral Nudges

DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer

Voice Therapy Per the Rehabilitation Treatment Specification System

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Randomized Controlled Trial of Two Mobile Health Strategies to Manage Postpartum Hypertension

Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations

South Asians With Type 2 Diabetes at Risk for Depression

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

About this NYU Langone Health institution page